ALGS (Aligos Therapeutics) Institutional Ownership: 48.09% (As of Jul. 11, 2026)


ALGS Aligos Therapeutics Inc ALGS
37 GF Score
Price $6.63
GF Value $2.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Institutional Ownership?

Aligos Therapeutics ALGS -2.22% 37 Institutional Ownership is 48.09% as of Jul. 11, 2026. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aligos Therapeutics's institutional ownership is 48.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aligos Therapeutics's Insider Ownership is 63.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aligos Therapeutics's Float Percentage Of Total Shares Outstanding is 84.81%.

Aligos Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Institutional Ownership Chart

Aligos Therapeutics Historical Data

The historical data trend for Aligos Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 4.87 5.21 5.54 5.65 5.77 5.85 5.32 5.36 5.43 5.73
ALGS
37GF Score
Aligos Therapeutics Inc ALGS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 48.09% mean?
Aligos Therapeutics (ALGS) has a Institutional Ownership of 48.09% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' Institutional Ownership too high?
Aligos Therapeutics' current Institutional Ownership is 48.09%. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Institutional Ownership compare to SNTI and NTRB?
Aligos Therapeutics' Institutional Ownership of 48.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current Institutional Ownership is 48.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current Institutional Ownership is 48.09%. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Institutional Ownership is 48.09% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • Institutional Ownership: 48.09%
  • GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score

Get the complete analysis for ALGS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63
Price
$2.78
GF Value